PCOS
MCID: PLY011
MIFTS: 65

Polycystic Ovary Syndrome (PCOS) malady

Categories: Rare diseases, Endocrine diseases

Aliases & Classifications for Polycystic Ovary Syndrome

Aliases & Descriptions for Polycystic Ovary Syndrome:

Name: Polycystic Ovary Syndrome 38 12 52 41 42 14 69
Pcos 12 50 14
Polycystic Ovaries 12 52
Polycystic Ovary 12 29
Polycystic Ovarian Syndrome 50
Polycystic Ovarian Disease 12
Stein-Leventhal Syndrome 12
Stein-Leventhal Synd. 12
Multicystic Ovaries 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11612
ICD10 33 E28.2
ICD9CM 35 256.4
MeSH 42 D011085
NCIt 47 C26862
UMLS 69 C0032460

Summaries for Polycystic Ovary Syndrome

MedlinePlus : 41 polycystic ovary syndrome (pcos) happens when a woman's ovaries or adrenal glands produce more male hormones than normal. pcos causes cysts (fluid-filled sacs) to grow on the ovaries. symptoms include irregular menstrual periods infertility pelvic pain excess hair growth on the face, chest, stomach, or thighs weight gain acne or oily skin patches of thickened skin women with pcos are at higher risk of diabetes, metabolic syndrome, heart disease, and high blood pressure. pcos is more common in women who are obese, or have a mother or sister with pcos. to diagnose pcos, your health care provider may do a physical exam, pelvic exam, blood tests, and an ultrasound. there is no cure, but diet, exercise, and medicines can help control the symptoms. birth control pills help women have normal periods, reduce male hormone levels, and clear acne. treatments for infertility caused by pcos may include medicines, surgery, and in vitro fertilization (ivf). nih: national institute of child health and human development

MalaCards based summary : Polycystic Ovary Syndrome, also known as pcos, is related to borderline personality disorder and thrombophilia, and has symptoms including pelvic pain An important gene associated with Polycystic Ovary Syndrome is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are p70S6K Signaling and PI3K-Akt signaling pathway. The drugs Metformin and Cyproterone Acetate have been mentioned in the context of this disorder. Affiliated tissues include ovary, heart and skin, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and endocrine/exocrine gland

NIH Rare Diseases : 50 polycystic ovarian syndrome (pcos) is a health problem that can affect a woman's menstrual cycle, ability to have children, hormones, heart, blood vessels, and appearance. women with this condition typically have high levels of  hormones called androgens, missed or irregular periods, and many small cysts in their ovaries. the cause of pcos is unknown, but probably involves a combination of genetic and environmental factors. treatment for pcos may involve birth control pills and medications for diabetes and infertility. medicines called anti-androgens are also used to speed the growth of hair and clear acne. last updated: 6/7/2016

Disease Ontology : 12 A syndrome characterized by hyperandrogenism, polycystic ovaries, hirsutism, oligomenorrhea or amenorrhea, anovulation and excessive body weight.

Wikipedia : 71 Polycystic ovary syndrome (PCOS) is a set of symptoms due to elevated androgens (male hormones) in... more...

Related Diseases for Polycystic Ovary Syndrome

Diseases in the Polycystic Ovary Syndrome family:

Polycystic Ovary Syndrome 1

Diseases related to Polycystic Ovary Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 199)
id Related Disease Score Top Affiliating Genes
1 borderline personality disorder 29.9 CYP17A1 CYP19A1 CYP21A2
2 thrombophilia 29.7 GHRL IGF1 IGFBP1 INS PRL
3 polycystic ovary syndrome 1 12.2
4 hyperandrogenism 11.4
5 aromatase deficiency 11.3
6 cortisone reductase deficiency 11.3
7 cortisone reductase deficiency 1 10.9
8 ovarian disease 10.9
9 hair-an syndrome 10.9
10 ovarian cyst 10.9
11 obesity 10.9
12 infertility 10.5
13 endotheliitis 10.4
14 intellectual disability-developmental delay-contractures syndrome 10.4 INS INSR
15 anovulation 10.3
16 brain angioma 10.3 IGF1 IRS1
17 diarrhea 3, secretory sodium, congenital, syndromic 10.3 IGF1 INS INSR
18 dacryoadenitis 10.3 IGF1 INS PRL
19 glucose intolerance 10.3
20 protein s deficiency 10.3 IGF1 INS PRL
21 glioblastoma mesenchymal subtype 10.3 CYP19A1 PRL SHBG
22 vertebral artery occlusion 10.3 GNRH1 INS PRL
23 olfactory nerve neoplasm 10.3 GNRH1 INS PRL
24 capillary disease 10.3 CYP19A1 PRL SHBG
25 diabetes mellitus, insulin-dependent, 2 10.3 IGFBP1 INS SHBG
26 leg dermatosis 10.3 INS INSR LEP SHBG
27 chondroma 10.3 IGF1 INS LEP
28 aflatoxins-related hepatocellular carcinoma 10.3 IGF1 INS PRL SHBG
29 stomach carcinoma in situ 10.3 IGF1 SHBG SULT2A1
30 fetal warfarin syndrome 10.3 IGF1 INS INSR LEP
31 astroblastoma 10.3 GNRH1 PRL SHBG
32 cervix squamous papilloma 10.3 IGF1 INS PRL
33 diencephalic neoplasm 10.3 GNRH1 INS PRL
34 adams-oliver syndrome 6 10.3 CYP19A1 GNRH1 INS
35 retroperitoneal sarcoma 10.2 GNRH1 PRL SHBG
36 limb ischemia 10.2 IGF1 INS LEP
37 neurogenic arthropathy 10.2 IGF1 INS IRS1 LEP
38 hyperinsulinemic hypoglycemia, familial, 5 10.2 IGF1 INS INSR IRS1
39 bile acid synthesis defect, congenital, 4 10.2 GNRH1 IGF1 PRL
40 diabetic encephalopathy 10.2 GHRL IGF1 INS LEP
41 insulin-like growth factor i 10.2
42 vestibular gland benign neoplasm 10.2 IGF1 INS PRL
43 urethra clear cell adenocarcinoma 10.2 GNRH1 IGF1 INS PRL
44 meningitis 10.2 INS INSR IRS1 LEP
45 gaucher's disease 10.2 CYP19A1 GNRH1 PRL SHBG
46 mucopolysaccharidosis iii 10.2 GHRL INS LEP
47 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 10.2 GHRL IGF1 LEP PRL
48 necrobiosis lipoidica 10.2 IGF1 PRL SHBG
49 nephrogenic adenofibroma 10.2 CYP19A1 GNRH1 LEP
50 thyroiditis 10.2

Graphical network of the top 20 diseases related to Polycystic Ovary Syndrome:



Diseases related to Polycystic Ovary Syndrome

Symptoms & Phenotypes for Polycystic Ovary Syndrome

UMLS symptoms related to Polycystic Ovary Syndrome:


pelvic pain

GenomeRNAi Phenotypes related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.78 IGF1 LEP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.78 LEP
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.78 IGF1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.78 IGF1 CYP21A2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.78 INSR
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 9.78 IGF1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.78 CYP21A2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.78 IGF1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.78 INSR
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.78 CYP21A2
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.78 SHBG
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 9.78 IGF1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.78 IGF1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.78 CYP21A2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.78 CYP21A2
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.78 IGF1 INSR LEP SHBG CYP21A2
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.78 LEP
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.78 IGF1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.78 INSR
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.78 LEP
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.78 INSR
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.78 INSR
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.78 IGF1

MGI Mouse Phenotypes related to Polycystic Ovary Syndrome:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.35 GNRH1 IGF1 INS INSR IRS1 LEP
2 homeostasis/metabolism MP:0005376 10.31 IGF1 INS INSR IRS1 LEP PRL
3 cellular MP:0005384 10.25 CYP11A1 CYP17A1 CYP19A1 FSHR FST IGF1
4 cardiovascular system MP:0005385 10.22 CYP19A1 FSHR FST IGF1 INS INSR
5 adipose tissue MP:0005375 10.19 CAPN10 CYP19A1 FSHR GHRL IGF1 INS
6 immune system MP:0005387 10.18 CAPN10 CYP11A1 CYP19A1 FSHR GNRH1 IGF1
7 hematopoietic system MP:0005397 10.16 INSR IRS1 LEP CAPN10 CYP11A1 CYP19A1
8 digestive/alimentary MP:0005381 10.04 CYP19A1 FST GHRL GNRH1 INS INSR
9 liver/biliary system MP:0005370 10.02 IRS1 LEP PRL CAPN10 CYP11A1 CYP19A1
10 integument MP:0010771 9.97 CYP19A1 FSHR FST GNRH1 IGF1 INS
11 muscle MP:0005369 9.86 CYP11A1 CYP19A1 FST IGF1 INS INSR
12 reproductive system MP:0005389 9.77 CYP11A1 CYP17A1 CYP19A1 FSHR FST GDF9
13 renal/urinary system MP:0005367 9.7 CAPN10 CYP19A1 GNRH1 IGF1 INS INSR
14 skeleton MP:0005390 9.28 CYP17A1 CYP19A1 FSHR FST GNRH1 IGF1

Drugs & Therapeutics for Polycystic Ovary Syndrome

Drugs for Polycystic Ovary Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 322)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
2
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 427-51-0
3
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-28-2 5757 53477783
4
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-63-6 5991
5
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
6
Ganirelix Approved Phase 4,Early Phase 1 123246-29-7, 124904-93-4 25081094
7
Drospirenone Approved Phase 4,Phase 3,Phase 1 67392-87-4 68873
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
9
Pioglitazone Approved, Investigational Phase 4,Early Phase 1 111025-46-8 4829
10
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
11
Zinc Approved Phase 4,Early Phase 1 7440-66-6 32051 23994
12
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Early Phase 1 57-83-0 5994
13
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
14
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
15
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
16
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 1 71-58-9
17 Moxonidine Approved Phase 4 75438-57-2 4810
18
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3 616-91-1 12035
19
Liraglutide Approved Phase 4 204656-20-2
20
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
21
Citalopram Approved Phase 4 59729-33-8 2771
22
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
23
Leuprolide Approved, Investigational Phase 4,Phase 2 53714-56-0 3911 657181
24
Menotropins Approved Phase 4,Phase 1,Phase 2 61489-71-2 5360545
25
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
26
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
27
Alogliptin Approved Phase 4 850649-61-5 11450633
28
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
29
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
30
Tamoxifen Approved Phase 4 10540-29-1 2733526
31
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2 141758-74-9 15991534
32
Desogestrel Approved Phase 4 54024-22-5 40973
33
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
34
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59-30-3 6037
36
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3 58-05-9 54575, 6560146 143
37
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 6221 10883523 5280795
38
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
39
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
40
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
41
Nicotinamide Approved, Nutraceutical Phase 4 98-92-0 936
42
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
43
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
44
Enclomiphene Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15690-57-0
45
Resveratrol Experimental, Investigational Phase 4,Phase 3,Phase 1 501-36-0, 955365-80-7 24856436 445154
46 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Androgen Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
48 Androgens Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
49 Contraceptive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
50 Contraceptive Agents, Male Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 520)
id Name Status NCT ID Phase
1 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4
2 the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome Unknown status NCT01752270 Phase 4
3 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4
4 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4
5 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4
6 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
7 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
8 PCOS, Therapy and Markers of Cardiovascular Risk Unknown status NCT01798875 Phase 4
9 Metformin in Step-down Regimen Versus Conventional Low Dose Step-up Protocol in Patients With PCOS Undergoing IVF Unknown status NCT01438190 Phase 4
10 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4
11 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4
12 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4
13 Adding L-carnitine in Clomiphene Resistant Polycystic Ovary Improves the Quality of Ovulation and the Pregnancy Outcome Unknown status NCT01665547 Phase 4
14 Corifollitropin Alfa Application in PCOS Patients Unknown status NCT02215135 Phase 4
15 Polycystic Ovary Syndrome - Improving Outcomes Completed NCT01504321 Phase 4
16 Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome Completed NCT00679679 Phase 4
17 PCOSMIC Trial - PolyCystic Ovary Syndrome, Metformin for Infertility With Clomiphene Completed NCT00795808 Phase 4
18 N-acetyl Cysteine for Ovulation Induction in Clomiphene Citrate Resistant Polycystic Ovary Syndrome Completed NCT02239107 Phase 4
19 The Effects of Fish Oils on Blood Pressure, Heart Rate Variability and Liver Fat in the Polycystic Ovary Syndrome Completed NCT00620529 Phase 4
20 Trial With Metformin in Women With Polycystic Ovary Syndrome Completed NCT02280057 Phase 4
21 Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome Completed NCT01118598 Phase 4
22 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism Completed NCT01360996 Phase 4
23 LIPT - Liraglutide in Polycystic Ovary Syndrome Completed NCT02073929 Phase 4
24 The Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination Completed NCT01219101 Phase 4
25 Metformin and Folate Supplementation in Polycystic Ovary Syndrome (PCOS) Patients Completed NCT00953355 Phase 4
26 Pioglitazone Treatment in Polycystic Ovary Syndrome Completed NCT00145340 Phase 4
27 The Effects of Vitamin D on Transforming Growth Factor-beta1 in Polycystic Ovary Syndrome Completed NCT02460380 Phase 4
28 Short-term Structured Exercise Training Program Plus Diet Intervention in Patients With Polycystic Ovary Syndrome (PCOS) Completed NCT01004068 Phase 4
29 Study of Mechanisms of Anovulation in Polycystic Ovary Syndrome Completed NCT00492882 Phase 4
30 Metformin and Folate in Pregnant Polycystic Ovary Syndrome(PCOS) Women Completed NCT01115140 Phase 4
31 Polycystic Ovary Syndrome and Liraglutide Completed NCT01899430 Phase 4
32 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4
33 Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study Completed NCT00640224 Phase 4
34 The Effect of Cipralex on Quality of Life, Adrenal Activity Glucose Metabolism, Physical and Mental Health in PCOS Completed NCT01961180 Phase 4
35 Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS Completed NCT00428311 Phase 4
36 Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin Completed NCT01911468 Phase 4
37 PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome Completed NCT02037672 Phase 4
38 PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome Completed NCT02187250 Phase 4
39 Metformin Suspension and Insulin Sensitivity Completed NCT00437333 Phase 4
40 Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles Completed NCT01233206 Phase 4
41 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS) Completed NCT00805935 Phase 4
42 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4
43 Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome Completed NCT01540747 Phase 4
44 Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome Completed NCT01675843 Phase 4
45 Epicardial Adipose Tissue Thickness in Polycystic Ovary Syndrome (PCOS) Completed NCT01258946 Phase 4
46 Second-Line Treatments for Anovulatory Infertility in PCOS Patients Completed NCT00558077 Phase 4
47 Metformin and Oral Contraceptives in PCOS Completed NCT00451568 Phase 4
48 Treatment of Anovulatory Infertility in PCOS Patients Completed NCT00471523 Phase 4
49 Medical Nutrition Therapy Plus Transgestational Metformin For Preventing Gestational Diabetes In High Risk Mexican Women Completed NCT01675310 Phase 4
50 Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome Completed NCT03122041 Phase 4

Search NIH Clinical Center for Polycystic Ovary Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: polycystic ovary syndrome

Genetic Tests for Polycystic Ovary Syndrome

Genetic tests related to Polycystic Ovary Syndrome:

id Genetic test Affiliating Genes
1 Polycystic Ovaries 29

Anatomical Context for Polycystic Ovary Syndrome

MalaCards organs/tissues related to Polycystic Ovary Syndrome:

39
Ovary, Heart, Skin, Testes, Endothelial, Adrenal Gland, Adipocyte

Publications for Polycystic Ovary Syndrome

Articles related to Polycystic Ovary Syndrome:

(show top 50) (show all 2318)
id Title Authors Year
1
Erratum: Combined letrozole and clomiphene versus letrozole and clomiphene alone in infertile patients with polycystic ovary syndrome [Erratum]. ( 28496306 )
2017
2
Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome. ( 28525998 )
2017
3
Follicular fluid cytokine composition and oocyte quality of polycystic ovary syndrome patients with metabolic syndrome undergoing in vitro fertilization. ( 28082237 )
2017
4
Circulatory microRNA 23a and microRNA 23b and polycystic ovary syndrome (PCOS): the effects of body mass index and sex hormones in an Eastern Han Chinese population. ( 28193283 )
2017
5
Family-Based Association Study of rs17300539 and rs12495941 Polymorphism in Adiponectin Gene and Polycystic Ovary Syndrome in a Chinese Population. ( 28060790 )
2017
6
Brown adipose tissue activation by rutin ameliorates polycystic ovary syndrome in rat. ( 28501702 )
2017
7
Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: a randomized controlled clinical trial. ( 28485095 )
2017
8
Phenotype and Tissue Expression as a Function of Genetic Risk in Polycystic Ovary Syndrome. ( 28068351 )
2017
9
Elevated serum interferon I^-inducible protein-10 in women with polycystic ovary syndrome. ( 28051885 )
2017
10
Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. ( 28479118 )
2017
11
A Comparison of Sexual Function in Women with Polycystic Ovary Syndrome (PCOS) Whose Mothers Had PCOS During Their Pregnancy Period with Those Without PCOS. ( 28070801 )
2017
12
Operative transvaginal hydrolaparoscopy improve ovulation rate after clomiphene failure in polycystic ovary syndrome. ( 28494682 )
2017
13
Ovarian Volume in Korean Women with Polycystic Ovary Syndrome and Its Related Factors. ( 28523256 )
2017
14
High free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independently of obesity and insulin resistance. ( 28487551 )
2017
15
Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. ( 28483503 )
2017
16
Quantification of visceral adipose tissue in polycystic ovary syndrome: dual-energy X-ray absorptiometry versus magnetic resonance imaging. ( 28534418 )
2017
17
Alterations in Gut Microbiome Composition and Barrier Function Are Associated with Reproductive and Metabolic Defects in Women with Polycystic Ovary Syndrome (PCOS): A Pilot Study. ( 28045919 )
2017
18
Pathologic significance of SET/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS). ( 27836688 )
2017
19
Single nucleotide polymorphisms in the TGF-I^1 gene are associated with polycystic ovary syndrome susceptibility and characteristics: a study in Korean women. ( 27796807 )
2017
20
Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3-iodothyronamine. ( 28082426 )
2017
21
The relationship between thyroid function and metabolic changes in Chinese women with polycystic ovary syndrome. ( 28051891 )
2017
22
The predictive effect of inflammatory markers and lipid accumulation product index on clinical symptoms associated with polycystic ovary syndrome in nonobese adolescents and younger aged women. ( 28535403 )
2017
23
Cardiovascular autonomic dysfunction in women with polycystic ovary syndrome: a systematic review and meta-analysis. ( 28483340 )
2017
24
The relationship between lipocalin-2 and free testosterone levels in polycystic ovary syndrome. ( 28255975 )
2017
25
Combining a nontargeted and targeted metabolomics approach to identify metabolic pathways significantly altered in polycystic ovary syndrome. ( 28521878 )
2017
26
Pathogenic Anti-MA1llerian Hormone Variants in Polycystic Ovary Syndrome. ( 28505284 )
2017
27
Microparticles: Inflammatory and haemostaticbiomarkers in Polycystic Ovary Syndrome. ( 28088464 )
2017
28
Views of women with polycystic ovary syndrome: a qualitative study in an ethnically diverse sample. ( 28515051 )
2017
29
Heart rate variability in normal-weight patients with polycystic ovary syndrome. ( 28529287 )
2017
30
Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. ( 28089571 )
2017
31
New diagnosis of polycystic ovary syndrome. ( 28082338 )
2017
32
Relationship between IL-17 serum level and ambulatory blood pressure in women with polycystic ovary syndrome. ( 28042549 )
2017
33
Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trial. ( 28058854 )
2017
34
Expression Patterns and Correlations with Metabolic Markers of Zinc Transporters ZIP14 and ZNT1 in Obesity and Polycystic Ovary Syndrome. ( 28303117 )
2017
35
Exaggerated glucagon responses to hypoglycemia in women with polycystic ovary syndrome. ( 28521865 )
2017
36
A homozygous mutation of GNRHR in a familial case diagnosed with polycystic ovary syndrome. ( 28348023 )
2017
37
The association of the lipidomic profile with features of polycystic ovary syndrome. ( 28500248 )
2017
38
Promoter methylation of yes-associated protein (YAP1) gene in polycystic ovary syndrome. ( 28079802 )
2017
39
Insulin sensitizers in adolescents with polycystic ovary syndrome. ( 28497664 )
2017
40
The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression of lipoprotein(a) and oxidized low-density lipoprotein, lipid profiles and biomarkers of oxidative stress in patients with polycystic ovary syndrome. ( 27619403 )
2016
41
Correlation of clinical and biochemical hyperandrogenism in Thai women with polycystic ovary syndrome. ( 26890011 )
2016
42
The Role of Anti-MA1llerian Hormone in the Characterization of the Different Polycystic Ovary Syndrome Phenotypes. ( 26718304 )
2016
43
Cortisol-Metabolizing Enzymes in Polycystic Ovary Syndrome. ( 27168731 )
2016
44
"It's not very feminine to have a mustache": Experiences of Danish women with polycystic ovary syndrome. ( 27630044 )
2016
45
Interleukin 10 (-A 1082 G/A) and (-A 819 C/T) gene polymorphisms in Egyptian women with polycystic ovary syndrome (PCOS). ( 27617227 )
2016
46
The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. ( 27459230 )
2016
47
Should we individualize lipid profiling in women with polycystic ovary syndrome? ( 27664213 )
2016
48
Vitamin D Status Relates to Reproductive Outcome in Women with Polycystic Ovary Syndrome: Secondary Analysis of a Multicenter Randomized Controlled Trial. ( 27186859 )
2016
49
MANAGEMENT OF ENDOCRINE DISEASE: Secondary polycystic ovary syndrome: theoretical and practical aspects. ( 27170519 )
2016
50
A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. ( 26969461 )
2016

Variations for Polycystic Ovary Syndrome

Expression for Polycystic Ovary Syndrome

Search GEO for disease gene expression data for Polycystic Ovary Syndrome.

Pathways for Polycystic Ovary Syndrome

Pathways related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

(show all 29)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.97 GDF9 GNRH1 IGF1 INS INSR IRS1
2 12.49 IGF1 INS INSR IRS1 PRL
3
Show member pathways
12.34 CYP17A1 INS IRS1 LEP PRL
4 12.31 CYP11A1 CYP19A1 IGFBP1 INS INSR IRS1
5
Show member pathways
12.27 IGF1 INS INSR IRS1 LEP
6
Show member pathways
12.16 GHRL IGF1 INS LEP
7
Show member pathways
12.11 INS INSR IRS1 LEP
8
Show member pathways
12.03 IGF1 INS INSR IRS1
9
Show member pathways
11.96 IGF1 INS INSR IRS1
10 11.93 IGF1 INS IRS1 LEP
11 11.81 IGF1 INS INSR
12 11.79 IGF1 INS LEP
13
Show member pathways
11.79 INS INSR IRS1
14 11.77 CYP11A1 CYP21A2 SULT2A1
15 11.6 INS INSR IRS1
16
Show member pathways
11.6 CYP11A1 CYP17A1 CYP19A1 CYP21A2 SRD5A1
17
Show member pathways
11.5 CYP17A1 CYP19A1 SULT2A1
18 11.49 INS INSR IRS1
19 11.42 FST IGF1 INS
20
Show member pathways
11.36 CYP11A1 CYP17A1 CYP19A1 CYP21A2 SRD5A1
21 11.35 INS INSR IRS1
22 11.19 IGF1 INS INSR IRS1
23 11.16 CYP19A1 FSHR GDF9
24 11.05 INS INSR IRS1 LEP PRL
25 10.95 INSR IRS1 LEP
26 10.92 CYP11A1 CYP17A1 CYP19A1 FSHR GDF9 IGF1
27
Show member pathways
10.9 CYP17A1 CYP21A2 SRD5A1
28
Show member pathways
10.85 INSR IRS1
29 10.73 FSHR GNRH1

GO Terms for Polycystic Ovary Syndrome

Cellular components related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 FST GDF9 GHRL GNRH1 IGF1 IGFBP1
2 endosome lumen GO:0031904 9.16 INS PRL
3 insulin receptor complex GO:0005899 8.62 INSR IRS1

Biological processes related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

(show all 34)
id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.92 IGF1 IGFBP1 INS PRL
2 positive regulation of cell proliferation GO:0008284 9.91 GDF9 IGF1 INS INSR IRS1 LEP
3 glucose homeostasis GO:0042593 9.85 INS INSR IRS1 LEP
4 response to estradiol GO:0032355 9.83 LEP PRL SRD5A1
5 female pregnancy GO:0007565 9.83 GNRH1 LEP PRL
6 positive regulation of protein kinase B signaling GO:0051897 9.81 INS INSR LEP
7 positive regulation of MAPK cascade GO:0043410 9.81 IGF1 INS INSR LEP
8 cellular response to insulin stimulus GO:0032869 9.8 CAPN10 INSR IRS1 SRD5A1
9 glucose metabolic process GO:0006006 9.79 GHRL INS LEP
10 insulin receptor signaling pathway GO:0008286 9.78 IGFBP1 INS INSR IRS1
11 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.76 FSHR IGF1 INS LEP
12 positive regulation of DNA replication GO:0045740 9.73 IGF1 INS INSR
13 steroid metabolic process GO:0008202 9.72 CYP11A1 CYP17A1 CYP21A2 SRD5A1 SULT2A1
14 activation of protein kinase B activity GO:0032148 9.71 IGF1 INS INSR
15 positive regulation of mitotic nuclear division GO:0045840 9.7 IGF1 INS INSR
16 androgen metabolic process GO:0008209 9.66 CYP19A1 SRD5A1
17 uterus development GO:0060065 9.66 CYP19A1 FSHR
18 insulin-like growth factor receptor signaling pathway GO:0048009 9.65 IGF1 IRS1
19 male sex determination GO:0030238 9.64 GNRH1 INSR
20 androgen biosynthetic process GO:0006702 9.63 CYP17A1 SRD5A1
21 ovulation cycle GO:0042698 9.63 GNRH1 PRL
22 adult feeding behavior GO:0008343 9.62 GHRL LEP
23 progesterone metabolic process GO:0042448 9.61 CYP17A1 SRD5A1
24 positive regulation of glycolytic process GO:0045821 9.61 IGF1 INS INSR
25 glucocorticoid biosynthetic process GO:0006704 9.6 CYP17A1 CYP21A2
26 positive regulation of respiratory burst GO:0060267 9.59 INS INSR
27 female genitalia development GO:0030540 9.58 CYP19A1 SRD5A1
28 positive regulation of developmental growth GO:0048639 9.58 INSR LEP
29 positive regulation of insulin receptor signaling pathway GO:0046628 9.58 INS IRS1 LEP
30 bone mineralization involved in bone maturation GO:0035630 9.57 IGF1 LEP
31 sterol metabolic process GO:0016125 9.56 CYP11A1 CYP17A1 CYP19A1 CYP21A2
32 steroid biosynthetic process GO:0006694 9.55 CYP11A1 CYP17A1 CYP19A1 CYP21A2 SRD5A1
33 positive regulation of glycogen biosynthetic process GO:0045725 9.26 IGF1 INS INSR IRS1
34 positive regulation of glucose import GO:0046326 9.02 CAPN10 IGF1 INS INSR IRS1

Molecular functions related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 iron ion binding GO:0005506 9.67 CYP11A1 CYP17A1 CYP19A1 CYP21A2
2 heme binding GO:0020037 9.62 CYP11A1 CYP17A1 CYP19A1 CYP21A2
3 insulin-like growth factor I binding GO:0031994 9.46 IGFBP1 INSR
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.46 CYP11A1 CYP17A1 CYP19A1 CYP21A2
5 steroid hydroxylase activity GO:0008395 9.43 CYP19A1 CYP21A2
6 insulin receptor binding GO:0005158 9.43 IGF1 INS IRS1
7 insulin-like growth factor II binding GO:0031995 9.4 IGFBP1 INSR
8 insulin-like growth factor receptor binding GO:0005159 9.26 IGF1 INS INSR IRS1
9 hormone activity GO:0005179 9.1 GHRL GNRH1 IGF1 INS LEP PRL

Sources for Polycystic Ovary Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....